Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders

IWWM-7 consensus

Meletios A. Dimopoulos, Efstathios Kastritis, Roger G. Owen, Robert A. Kyle, Ola Landgren, Enrica Morra, Xavier Leleu, Ramón García-Sanz, Nikhil Munshi, Kenneth C. Anderson, Evangelos Terpos, Irene M. Ghobrial, Pierre Morel, David Maloney, Mathias Rummel, Véronique Leblond, Ranjana H. Advani, Morie A. Gertz, Charalampia Kyriakou, Sheeba K. Thomas & 5 others Bart Barlogie, Stephanie A. Gregory, Eva Kimby, Giampaolo Merlini, Steven P. Treon

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of International Workshops on WM (IWWM). As part of the IWWM-7 and based on recently published and ongoing clinical trials, the panels updated treatment recommendations. Therapeutic strategy in WM should be based on individual patient and disease characteristics (age, comorbidities, need for rapid disease control, candidacy for autologous transplantation, cytopenias, IgM-related complications, hyperviscosity, and neuropathy). Mature data show that rituximab combinations with cyclophosphamide/ dexamethasone, bendamustine, or bortezomib/dexamethasone provided durable responses and are indicatedformostpatients. Newmonoclonalan-tibodies (ofatumumab), second-generation proteasome inhibitors (carfilzomib), mam-malian target of rapamycin inhibitors, and Bruton's tyrosine kinase inhibitors are promising and may expand future treatment options. A different regimen is typically recommended for relapsed or refractory disease. In selected patients with relapsed disease after long-lasting remission, reuse of a prior effective regimen may be appropriate. Autologous stem cell transplantation may be considered in young patients with chemosensitive disease and in newly diagnosed patients with very-high-risk features. Active enrollment of patients with WM in clinical trials is encouraged.

Original languageEnglish
Pages (from-to)1404-1411
Number of pages8
JournalBlood
Volume124
Issue number9
DOIs
Publication statusPublished - Aug 28 2014

Fingerprint

Waldenstrom Macroglobulinemia
Education
Dexamethasone
Disease control
Proteasome Inhibitors
Clinical Trials
Sirolimus
Therapeutics
Stem cells
Refractory materials
Lymphoproliferative Disorders
Cyclophosphamide
Autologous Transplantation
Immunoglobulin M
Stem Cell Transplantation
Cells
Comorbidity
B-Lymphocytes

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology
  • Medicine(all)

Cite this

Dimopoulos, M. A., Kastritis, E., Owen, R. G., Kyle, R. A., Landgren, O., Morra, E., ... Treon, S. P. (2014). Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood, 124(9), 1404-1411. https://doi.org/10.1182/blood-2014-03-565135

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders : IWWM-7 consensus. / Dimopoulos, Meletios A.; Kastritis, Efstathios; Owen, Roger G.; Kyle, Robert A.; Landgren, Ola; Morra, Enrica; Leleu, Xavier; García-Sanz, Ramón; Munshi, Nikhil; Anderson, Kenneth C.; Terpos, Evangelos; Ghobrial, Irene M.; Morel, Pierre; Maloney, David; Rummel, Mathias; Leblond, Véronique; Advani, Ranjana H.; Gertz, Morie A.; Kyriakou, Charalampia; Thomas, Sheeba K.; Barlogie, Bart; Gregory, Stephanie A.; Kimby, Eva; Merlini, Giampaolo; Treon, Steven P.

In: Blood, Vol. 124, No. 9, 28.08.2014, p. 1404-1411.

Research output: Contribution to journalArticle

Dimopoulos, MA, Kastritis, E, Owen, RG, Kyle, RA, Landgren, O, Morra, E, Leleu, X, García-Sanz, R, Munshi, N, Anderson, KC, Terpos, E, Ghobrial, IM, Morel, P, Maloney, D, Rummel, M, Leblond, V, Advani, RH, Gertz, MA, Kyriakou, C, Thomas, SK, Barlogie, B, Gregory, SA, Kimby, E, Merlini, G & Treon, SP 2014, 'Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus', Blood, vol. 124, no. 9, pp. 1404-1411. https://doi.org/10.1182/blood-2014-03-565135
Dimopoulos, Meletios A. ; Kastritis, Efstathios ; Owen, Roger G. ; Kyle, Robert A. ; Landgren, Ola ; Morra, Enrica ; Leleu, Xavier ; García-Sanz, Ramón ; Munshi, Nikhil ; Anderson, Kenneth C. ; Terpos, Evangelos ; Ghobrial, Irene M. ; Morel, Pierre ; Maloney, David ; Rummel, Mathias ; Leblond, Véronique ; Advani, Ranjana H. ; Gertz, Morie A. ; Kyriakou, Charalampia ; Thomas, Sheeba K. ; Barlogie, Bart ; Gregory, Stephanie A. ; Kimby, Eva ; Merlini, Giampaolo ; Treon, Steven P. / Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders : IWWM-7 consensus. In: Blood. 2014 ; Vol. 124, No. 9. pp. 1404-1411.
@article{cc88dca45031495ab98606af2d0afcec,
title = "Treatment recommendations for patients with Waldenstr{\"o}m macroglobulinemia (WM) and related disorders: IWWM-7 consensus",
abstract = "Waldenstr{\"o}m macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of International Workshops on WM (IWWM). As part of the IWWM-7 and based on recently published and ongoing clinical trials, the panels updated treatment recommendations. Therapeutic strategy in WM should be based on individual patient and disease characteristics (age, comorbidities, need for rapid disease control, candidacy for autologous transplantation, cytopenias, IgM-related complications, hyperviscosity, and neuropathy). Mature data show that rituximab combinations with cyclophosphamide/ dexamethasone, bendamustine, or bortezomib/dexamethasone provided durable responses and are indicatedformostpatients. Newmonoclonalan-tibodies (ofatumumab), second-generation proteasome inhibitors (carfilzomib), mam-malian target of rapamycin inhibitors, and Bruton's tyrosine kinase inhibitors are promising and may expand future treatment options. A different regimen is typically recommended for relapsed or refractory disease. In selected patients with relapsed disease after long-lasting remission, reuse of a prior effective regimen may be appropriate. Autologous stem cell transplantation may be considered in young patients with chemosensitive disease and in newly diagnosed patients with very-high-risk features. Active enrollment of patients with WM in clinical trials is encouraged.",
author = "Dimopoulos, {Meletios A.} and Efstathios Kastritis and Owen, {Roger G.} and Kyle, {Robert A.} and Ola Landgren and Enrica Morra and Xavier Leleu and Ram{\'o}n Garc{\'i}a-Sanz and Nikhil Munshi and Anderson, {Kenneth C.} and Evangelos Terpos and Ghobrial, {Irene M.} and Pierre Morel and David Maloney and Mathias Rummel and V{\'e}ronique Leblond and Advani, {Ranjana H.} and Gertz, {Morie A.} and Charalampia Kyriakou and Thomas, {Sheeba K.} and Bart Barlogie and Gregory, {Stephanie A.} and Eva Kimby and Giampaolo Merlini and Treon, {Steven P.}",
year = "2014",
month = "8",
day = "28",
doi = "10.1182/blood-2014-03-565135",
language = "English",
volume = "124",
pages = "1404--1411",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders

T2 - IWWM-7 consensus

AU - Dimopoulos, Meletios A.

AU - Kastritis, Efstathios

AU - Owen, Roger G.

AU - Kyle, Robert A.

AU - Landgren, Ola

AU - Morra, Enrica

AU - Leleu, Xavier

AU - García-Sanz, Ramón

AU - Munshi, Nikhil

AU - Anderson, Kenneth C.

AU - Terpos, Evangelos

AU - Ghobrial, Irene M.

AU - Morel, Pierre

AU - Maloney, David

AU - Rummel, Mathias

AU - Leblond, Véronique

AU - Advani, Ranjana H.

AU - Gertz, Morie A.

AU - Kyriakou, Charalampia

AU - Thomas, Sheeba K.

AU - Barlogie, Bart

AU - Gregory, Stephanie A.

AU - Kimby, Eva

AU - Merlini, Giampaolo

AU - Treon, Steven P.

PY - 2014/8/28

Y1 - 2014/8/28

N2 - Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of International Workshops on WM (IWWM). As part of the IWWM-7 and based on recently published and ongoing clinical trials, the panels updated treatment recommendations. Therapeutic strategy in WM should be based on individual patient and disease characteristics (age, comorbidities, need for rapid disease control, candidacy for autologous transplantation, cytopenias, IgM-related complications, hyperviscosity, and neuropathy). Mature data show that rituximab combinations with cyclophosphamide/ dexamethasone, bendamustine, or bortezomib/dexamethasone provided durable responses and are indicatedformostpatients. Newmonoclonalan-tibodies (ofatumumab), second-generation proteasome inhibitors (carfilzomib), mam-malian target of rapamycin inhibitors, and Bruton's tyrosine kinase inhibitors are promising and may expand future treatment options. A different regimen is typically recommended for relapsed or refractory disease. In selected patients with relapsed disease after long-lasting remission, reuse of a prior effective regimen may be appropriate. Autologous stem cell transplantation may be considered in young patients with chemosensitive disease and in newly diagnosed patients with very-high-risk features. Active enrollment of patients with WM in clinical trials is encouraged.

AB - Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of International Workshops on WM (IWWM). As part of the IWWM-7 and based on recently published and ongoing clinical trials, the panels updated treatment recommendations. Therapeutic strategy in WM should be based on individual patient and disease characteristics (age, comorbidities, need for rapid disease control, candidacy for autologous transplantation, cytopenias, IgM-related complications, hyperviscosity, and neuropathy). Mature data show that rituximab combinations with cyclophosphamide/ dexamethasone, bendamustine, or bortezomib/dexamethasone provided durable responses and are indicatedformostpatients. Newmonoclonalan-tibodies (ofatumumab), second-generation proteasome inhibitors (carfilzomib), mam-malian target of rapamycin inhibitors, and Bruton's tyrosine kinase inhibitors are promising and may expand future treatment options. A different regimen is typically recommended for relapsed or refractory disease. In selected patients with relapsed disease after long-lasting remission, reuse of a prior effective regimen may be appropriate. Autologous stem cell transplantation may be considered in young patients with chemosensitive disease and in newly diagnosed patients with very-high-risk features. Active enrollment of patients with WM in clinical trials is encouraged.

UR - http://www.scopus.com/inward/record.url?scp=84907365372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907365372&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-03-565135

DO - 10.1182/blood-2014-03-565135

M3 - Article

VL - 124

SP - 1404

EP - 1411

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -